Moss 18 December, 2025
Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic
tests, today provided an update on the development of its turbidimetric
NT-proBNP assay, which remains the company's highest-priority pipeline project.
Throughout the fourth quarter of 2025, Gentian made solid progress in advancing
the assay toward final product verification. Continued refinement of the
calibration approach has led to further improvements in the assay's analytical
performance. To ensure a high-quality and robust product, the company has
prioritised additional refinement work ahead of the research-use-only (RUO)
introduction, leading to a minor delay compared with earlier expectations.
Clinical performance evaluations with external partners are ongoing, and the
company expects to provide an update on the RUO product during the first quarter
of 2026.
Gentian Diagnostics continues to target the launch of a CE-marked NT-proBNP
assay in the fourth quarter of 2026, in line with previous communication.
IR contact:
Njaal Kind, CEO
njaal.kind@gentian.no
+47 919 06 525 (mobile)
This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.